Phase 2 N=35 Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
Breast Cancer
Primary: Objective Response Rate (ORR) — 37.5 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy
Urinary Tract Infection · Vesicoureteral Reflux
Primary: Visualization of Renal Scars Compared to Previous Imaging — 100 Percentage of previous scars visualized
Phase 2 N=371 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Lymphoma · Nonneoplastic Condition
Primary: Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine…
Phase 2 N=9 Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Alzheimer's Disease
Primary: Percent Change From Baseline to End of Treatment in Cerebrospinal Fluid Levels of Cytokines — 137 percentage of baseline at Day 42
Phase 2 N=45 Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Episodic Migraine
Primary: Headache Days in Each Treatment Period Month — 7.1; 10.88; 7.05; 9.47 Number of Headache days
Phase 2 N=96 Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Phase 2 N=25 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Follicular Carcinoma
Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants
Phase 2 N=68 Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia
Primary: Progression-free Survival — 41.2; 26.9 percentage of patients
Phase 2 N=85 Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · Gastroesophageal Adenocarcinoma · Distal Esophageal Adenocarcinoma
Primary: Number of Participants With Progression at the 3 Month Follow up Visit — 15; 7 participants
Phase 2 N=5 Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Graft Versus Host Disease · Leukemia · Lymphoma
Primary: Transplantation-related Mortality at 100 Days Post-transplantation — 2 Participants
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Phase 2 N=48 Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Change From Baseline in 24 Hour UGE on Day 7 — -0.46; 64.63; 80.73; 97.64 gram per 24 hours (g/24 h) — p=<0.0001
Phase 2 N=15 Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Glioblastoma
Primary: 3-Month Progression-Free Survival (PFS3) — 0 Participants
Phase 2 N=4 Dose-finding Study in Platinum-Resistant Ovarian Cancer
Recurrent Platinum-resistant Ovarian Cancer
Primary: Phase 1: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) of Grade Greater Than or Equal to (≥) 3 in Severity — 26; 12; 6; 1 Participants
Phase 2 N=92 A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
Chronic Obstructive Pulmonary Disease, COPD
Primary: Change From Baseline in Lung Clearance Index (LCI) — -0.03; -0.16 Days — p=0.130